Organic Letters · 2013 · 63 citations · 33 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryProdrug DesignAnticancer Prodrug DesignEnzyme InhibitionNatural Product Drug DiscoveryOncology PharmacologyRedox-activated ProdrugsTumor-activated ProdrugsBioreductive ActivationCancer Cell Proliferation InhibitionCell-based AssaysDna Damage InductionNitric OxideNitric Oxide MetabolismNitroaromatic ProdrugsOxidative Dna Damage
The design, synthesis, and development of INDQ/NO, a novel nitric oxide (NO) prodrug targeted by a bioreductive trigger, are described. INDQ/NO, an indolequinone-diazeniumdiolate is found to be metabolized to produce NO by DT-diaphorase, a bioreductive enzyme that is overexpressed in certain cancers and hypoxic tumors. Cell-based assays revealed that INDQ/NO induces DNA damage and is a potent inhibitor of cancer cell proliferation.
33
Joseph E. Saavedra, Timothy R. Billiar, Debra L. Williams et al. · Journal of Medicinal Chemistry · 1997 · 275 citations